Imricor Medical Systems, Inc.ASX: IMR

FDA Accepts Imricor PMA Manufacturing Module

· Issued by Imricor Medical Systems, Inc. via ASX

Filed with ASX · · 3 pages · English

Summary by 6ix AI

Imricor Medical Systems, Inc. has announced that the FDA has accepted its Premarket Approval manufacturing module, marking a significant milestone in the approval process for its products. The closure of this module indicates that it will not be re-reviewed unless changes are made, bringing Imricor closer to final FDA approval. The FDA will conduct a pre-approval inspection of Imricor's manufacturing sites before any final approval is granted.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Imricor Medical Systems, Inc. (ASX: IMR) | ARBN 633 106 019 400 Gateway Blvd. | Burnsville, Minnesota 55337 USA | +1 952.818.8400 | imricor.com FDA ACCEPTS IMRICOR’S PMA MANUFACTURING MODULE Key Highlights • The U.S. Food and Drug Administration (FDA) has...

Imricor Medical Systems, Inc. on 6ix

Earlier from Imricor Medical Systems

Later from Imricor Medical Systems

All Imricor Medical Systems news releases